Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study |
| |
| Affiliation: | 1. Infectious Diseases Intervention Unit, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;2. Department of Haematology, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;3. Haematology-Bone Marrow Transplantation Unit, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;4. Pharmacy, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;5. Centre d''Epidémiologie Clinique, Centre Cochrane Français, Hôpital de l''Hôtel-Dieu, INSERM U738, APHP, Paris, France;6. Parasitology and Mycology Laboratory, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;7. Department of Pneumology, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;8. Department of Intensive Care Unit, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France;9. Department of Infectious Diseases, Hôpital Saint-Louis, APHP, University of Paris Diderot Paris 7, Paris, France |
| |
| Abstract: | Posaconazole (PSC) is currently recommended as primary prophylaxis in neutropenic patients with acute myeloid leukaemia (AML) and in allogenic haematopoietic stem cell transplantation (AHSCT) recipients with graft-versus-host disease (GVHD). Studies focusing on breakthrough invasive fungal disease (IFD) upon PSC prophylaxis show disparate results. In order to evaluate the incidence of IFD in patients on PSC prophylaxis and identify IFD risk factors, we carried out a retrospective study of all consecutive patients on PP from January 2007 to December 2010 in our hospital. Breakthrough IFDs were identified from the database of the central pharmacy and the French administrative database (PMSI), registering final medical diagnoses of hospitalized patients. Medical data were reviewed to study proven or probable IFD, according to EORTC/MSG definition. PSC plasma concentrations (PPC) were also retrieved. Poisson models were used for statistical analysis. Two hundred and seventy-nine patients received PSC prophylaxis for a median duration of 1.4 months (range 0.2–17.9). Proven (n = 6) or probable (n = 3) IFDs were diagnosed in nine cases (3.2%). IFD incidence rate per 100 person-month was 1.65 (95% CI, 0.79–2.97). IFDs were candidaemia (Candida glabrata, n = 2), pulmonary invasive aspergillosis (n = 3), disseminated fusariosis (n = 2) and pulmonary mucormycosis (n = 2). Seven deaths were reported, directly related to IFD in three patients (33.3%). First dosage of PPC under 0.3 mg/L was the single significant risk factor for IFD (RR, 7.77; 95% CI, 1.30–46.5; p 0.025). Breakthrough IFD in patients receiving PSC prophylaxis is rare but associated with a poor outcome. Low PSC plasma concentrations are associated with an increased risk of IFD. |
| |
| Keywords: | Antifungal prophylaxis candidaemia fusariosis invasive aspergillosis invasive fungal disease mucormycosis posaconazole therapeutic drug monitoring |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
